Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
336.80
+9.20 (2.81%)
Last updated: Jun 24, 2025
102.28%
Market Cap 74.28B
Revenue (ttm) 2.06B
Net Income (ttm) -283.88M
Shares Out 228.54M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 418,818
Average Volume 1,113,200
Open 334.00
Previous Close 327.60
Day's Range 318.20 - 340.00
52-Week Range 120.20 - 380.00
Beta n/a
RSI 48.13
Earnings Date Aug 19, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,837
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6990
Full Company Profile

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.